WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326935

CAS#: 110958-19-5

Description: Fasoracetam, also known as NS-105; NFC-1; LAM-105, is a GABA receptor modulator potentially for the treatment of attention deficit hyperactivity disorder. It is a nootropic, and has been in a clinical trial for attention deficit hyperactivity disorder. In in vitro studies on mouse neurons, fasoracetam modulated mGluR II/III activity. In studies in rats, it blocked memory disruptions caused by baclofen, a GABAB agonist and upregulated production of GABAB receptors after repeat dosing.

Price and Availability




Fasoracetam is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 326935
Name: Fasoracetam
CAS#: 110958-19-5
Chemical Formula: C10H16N2O2
Exact Mass: 196.1212
Molecular Weight: 196.25
Elemental Analysis: C, 61.20; H, 8.22; N, 14.27; O, 16.30

Related CAS #: 1618109-51-5 (tartrate)   2055646-53-0 (hydrate)   110958-19-5    

Synonym: Fasoracetam; N-(5-Oxo-D-prolyl)piperidine; NS-105; NFC-1; LAM-105.

IUPAC/Chemical Name: (R)-1-((5-Oxo-2-pyrrolidinyl)carbonyl)piperidine


InChi Code: InChI=1S/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Chugh G, Asghar M, Patki G, Bohat R, Jafri F, Allam F, Dao AT, Mowrey C, Alkadhi K, Salim S. A high-salt diet further impairs age-associated declines in cognitive, behavioral, and cardiovascular functions in male Fischer brown Norway rats. J Nutr. 2013 Sep;143(9):1406-13. doi: 10.3945/jn.113.177980. Epub 2013 Jul 17. PubMed PMID: 23864508; PubMed Central PMCID: PMC3743272.

2: Fasoracetam. LAM 105, NS 105. Drugs R D. 1999 Aug;2(2):135-6. PubMed PMID: 10820660.

3: Mukai H, Sugimoto T, Ago M, Morino A, Takaichi M, Ogawa Y, Seki H, Matsuura C, Esumi Y. Pharmacokinetics of NS-105, a novel cognition enhancer. 2nd communication: distribution and transfer into fetus and milk after single administration, and effects of repeated administration on pharmacokinetics and hepatic drug-metabolizing enzyme activities in rats. Arzneimittelforschung. 1999 Dec;49(12):977-85. PubMed PMID: 10635441.

4: Hirouchi M, Oka M, Itoh Y, Ukai Y, Kimura K. Role of metabotropic glutamate receptor subclasses in modulation of adenylyl cyclase activity by a nootropic NS-105. Eur J Pharmacol. 2000 Jan 3;387(1):9-17. PubMed PMID: 10633154.

5: Mukai H, Sugimoto T, Ago M, Morino A. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105. Arzneimittelforschung. 1999 Nov;49(11):881-90. PubMed PMID: 10604039.

6: Ogasawara T, Itoh Y, Tamura M, Mushiroi T, Ukai Y, Kise M, Kimura K. Involvement of cholinergic and GABAergic systems in the reversal of memory disruption by NS-105, a cognition enhancer. Pharmacol Biochem Behav. 1999 Sep;64(1):41-52. PubMed PMID: 10494996.

7: Kumagai Y, Yokota S, Isawa S, Murasaki M, Mukai H, Miyatake S. Comparison of pharmacokinetics of NS-105, a novel agent for cerebrovascular disease, in elderly and young subjects. Int J Clin Pharmacol Res. 1999;19(1):1-8. PubMed PMID: 10450537.

8: Shimidzu T, Itoh Y, Oka M, Ishima T, Ukai Y, Yoshikuni Y, Kimura K. Effect of a novel cognition enhancer NS-105 on learned helplessness in rats: possible involvement of GABA(B) receptor up-regulation after repeated treatment. Eur J Pharmacol. 1997 Nov 12;338(3):225-32. PubMed PMID: 9424016.

9: Oka M, Itoh Y, Tatsumi S, Ma FH, Ukai Y, Yoshikuni Y, Kimura K. A novel cognition enhancer NS-105 modulates adenylate cyclase activity through metabotropic glutamate receptors in primary neuronal culture. Naunyn Schmiedebergs Arch Pharmacol. 1997 Aug;356(2):189-96. PubMed PMID: 9272724.

10: Oka M, Itoh Y, Shimidzu T, Ukai Y, Yoshikuni Y, Kimura K. Involvement of metabotropic glutamate receptors in Gi- and Gs-dependent modulation of adenylate cyclase activity induced by a novel cognition enhancer NS-105 in rat brain. Brain Res. 1997 Apr 18;754(1-2):121-30. PubMed PMID: 9134967.

11: White RL. Review of current status of cochlear prostheses. IEEE Trans Biomed Eng. 1982 Apr;29(4):233-8. PubMed PMID: 6896043.